Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 342

1.

Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.

Ndumbi P, Gillis J, Raboud J, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas C; Canadian Observational Cohort (CANOC) Collaboration..

HIV Med. 2014 Mar;15(3):153-64. doi: 10.1111/hiv.12096.

2.

Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of successful HIV suppression.

Ndumbi P, Falutz J, Pant Pai N, Tsoukas CM.

PLoS One. 2014 Apr 7;9(4):e94018. doi: 10.1371/journal.pone.0094018.

3.

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I.

Clin Microbiol Infect. 2012 May;18(5):449-58. doi: 10.1111/j.1469-0691.2011.03650.x.

4.

Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration..

PLoS One. 2013 Oct 30;8(10):e77665. doi: 10.1371/journal.pone.0077665.

5.

Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.

Chow WZ, Lim SH, Ong LY, Yong YK, Takebe Y, Kamarulzaman A, Tee KK.

PLoS One. 2015 Sep 3;10(9):e0137281. doi: 10.1371/journal.pone.0137281.

6.

Clinical impact of altered T-cell homeostasis in treated HIV patients enrolled in a large observational cohort.

Ndumbi P, Gillis J, Raboud JM, Cooper C, Hogg RS, Montaner JS, Burchell AN, Loutfy MR, Machouf N, Klein MB, Tsoukas CM; Canadian Observational Cohort (CANOC) collaboration..

AIDS. 2013 Nov 28;27(18):2863-72. doi: 10.1097/01.aids.0000432471.84497.bc.

PMID:
25119689
7.

Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.

Hermans SM, Manabe YC, Kiragga AN, Hoepelman AI, Lange JM, van Leth F.

Antivir Ther. 2013;18(4):615-22. doi: 10.3851/IMP2525.

PMID:
23423604
8.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

9.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study..

Clin Infect Dis. 2005 Aug 1;41(3):361-72.

PMID:
16007534
10.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
11.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team..

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249.

PMID:
22805174
12.

Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.

Hocqueloux L, Avettand-Fènoël V, Jacquot S, Prazuck T, Legac E, Mélard A, Niang M, Mille C, Le Moal G, Viard JP, Rouzioux C; AC32 (Coordinated Action on HIV Reservoirs) of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS)..

J Antimicrob Chemother. 2013 May;68(5):1169-78. doi: 10.1093/jac/dks533.

PMID:
23335199
13.

CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.

Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC; Swiss HIV Cohort Study..

Antivir Ther. 2007;12(6):889-97.

PMID:
17926643
14.

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study..

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.

PMID:
18783328
15.

Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.

Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S; QUEST Study Group..

Clin Infect Dis. 2007 Aug 1;45(3):381-90.

PMID:
17599319
16.

Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.

Routy JP, Angel JB, Patel M, Kanagaratham C, Radzioch D, Kema I, Gilmore N, Ancuta P, Singer J, Jenabian MA.

HIV Med. 2015 Jan;16(1):48-56. doi: 10.1111/hiv.12171.

17.

Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.

Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)..

HIV Med. 2005 May;6(3):198-205.

18.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
19.

Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.

Cingolani A, Cozzi Lepri A, Castagna A, Goletti D, De Luca A, Scarpellini P, Fanti I, Antinori A, d'Arminio Monforte A, Girardi E.

Clin Infect Dis. 2012 Mar;54(6):853-61. doi: 10.1093/cid/cir900.

PMID:
22157323
20.

Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.

Pakker NG, Kroon ED, Roos MT, Otto SA, Hall D, Wit FW, Hamann D, van der Ende ME, Claessen FA, Kauffmann RH, Koopmans PP, Kroon FP, ten Napel CH, Sprenger HG, Weigel HM, Montaner JS, Lange JM, Reiss P, Schellekens PT, Miedema F.

AIDS. 1999 Feb 4;13(2):203-12.

PMID:
10202826
Items per page

Supplemental Content

Support Center